Table 2.

Primary outcome as composite endpoint and by event at Day 28, as well as logistic regression analysis. Full analysis set (FAS).

Group	hzVSF-v13 Low Dose (N = 22)	hzVSF-v13 High Dose (N = 21)	Placebo (N = 19)
Patients with clinical failure at Day 28 n (%)	2 (9.1)	2 (9.5)	3 (15.8)
Crude Odds Ratios (ORs)	0.53	0.56
85% Confidence Interval (CI)	[0.13, 2.16]	[0.14, 2.28]
p-value	0.5180	0.5533
Death n (%)	2 (9.1)	2 (9.5)	3 (15.8)
Crude ORs	0.53	0.56
85% CI	[0.13, 2.16]	[0.14, 2.28]
p-value	0.5180	0.5533
Respiratory failure n (%)	0	2 (9.5)	3 (15.8)
Crude ORs	0	0.56
85% CI		[0.14, 2.28]
p-value	0.9515	0.5533
Subjects with ICU Admission, n (%)	0	2 (9.5)	3 (15.8)
Crude ORs	0	0.56
85% CI		[0.14, 2.28]
p-value	0.9515	0.5533